Sign Out
Solid tumors: ROZLYTREK is indicated for the treatment of adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive locally advanced or metastatic solid tumors, who have progressed following prior therapies, or as initial therapy when there are no acceptable standard therapies.
Non-small cell lung cancer (NSCLC): ROZLYTREK is indicated for the treatment of patients with ROS1-positive, locally advanced or metastatic NSCLC.
